Inspira Technologies OXY BHN Ltd. has entered into a non-binding term sheet for the acquisition of an advanced liquid biopsy cancer diagnostics business, alongside a concurrent $15 million strategic equity investment based on a pre-money valuation of $180 million. The planned transaction is expected to expand Inspira's presence in the high-growth diagnostics market with a development-ready liquid biopsy platform that has a clear regulatory pathway and an established reimbursement code. The company intends to allocate $12 million from the investment to further develop its existing respiratory and blood monitoring technologies. A shareholder protection framework is also included to preserve the economic value of Inspira's current technology assets for existing shareholders. The identity of the strategic investor will be disclosed following shareholder approval and execution of definitive agreements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-000794), on January 05, 2026, and is solely responsible for the information contained therein.
Comments